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a b s t r a c t
After the implementation of standard ﬁrst line chemotherapy with platinum and antifolates in pleural
mesothelioma, patients are confronted with a need for second line treatment at relapse or progression.
We conducted a systematic review of the literature for the activity, effectiveness and toxicity of second
line treatment. The results are presented according to the class of drugs: chemotherapy and targeted or
biological agent.
© 2015 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Malignant pleural mesothelioma (MPM) is a cancer of the sur-
ace mesothelium of the pleural cavity. Over 80% of mesothelioma
atients have a history of previous intense occupational asbestos
xposure. A causal relation has been repeatedly documented,
lthough MPM can also result from very low levels of environ-
ental exposure [1]. The average latency of 40–45 years or more
ince the start of the exposure as found in studies with adequately
ong follow-up time explains the pattern of the observed mesothe-
ioma incidence increases over the last decades with an estimated
3,000 annual deaths worldwide and why substantial decreases
re not expected before 2020 [2]. Time trends indicate a slow shift
f disease burden to countries consuming asbestos most recently
3], while incidence has peaked in most western industrialized
ountries after the ban of asbestos import and use in the eighties
nd nineties of last century [4]. Other possible causes are ionizing
adiation, endemic erionite exposure and chronic inﬂammation of
he pleura [3].
MPM has a poor prognosis: most patients will die of their dis-
ase within less than one year of diagnosis, if untreated. Among the
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169-5002/© 2015 Elsevier Ireland Ltd. All rights reserved.reasons for this detrimental natural course are their insidious pre-
sentations in older patients with various comorbidities, its disease
extension at diagnosis, a lack of curative treatments and a certain
therapeutic nihilism among the medical profession.
With surgical resection being reserved for a small minority of
patients, the only intervention with proven impact on outcome is
palliative chemotherapy. One trial randomly compared ﬁrst line
chemotherapy (either mitomycin, vinblastine, cisplatin (MVP) or
vinorelbin)with active supportive care (ASC) [5]. Althoughnoover-
all survival (OS)beneﬁtor improvement inqualityof lifewas seen in
the intention-to-treat population, exploratory analyses suggested
a survival advantage for vinorelbine with a 2 months’ survival ben-
eﬁt over ASC that approached signiﬁcance, although these beneﬁts
were not seen for those patients who received MVP. Two random-
ized trials have further set the standard of care to a combination of
cisplatinwithanantifolate, eitherpemetrexedor raltitrexed [6,7]. A
complete analysis of the efﬁcacy and cost-effectiveness of ﬁrst-line
chemotherapy inMPMshowed that both scheduleswerenotdiffer-
ent in termsof response rate (RR), time-to-progression (TTP) andOS
[8]. The implementation of novel ﬁrst line chemotherapy has been
associated with a population-based improvement in outcome over
time [9].
With a median TTP of 5.5 months and 25% of patients refrac-
tory to ﬁrst line chemotherapy, increasing numbers of patients are
now likely to be candidate for second line treatment. A systematic
review concluded in 2010 that no cytostatic, immunomodulating
or targeted drug had been validated in second-line chemotherapy
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nd patients in a good performance status should be recommended
o enter clinical trials [10]. We updated this systematic review.
. Methods
The search for prospective published trials relative to the sec-
nd line treatmentofmalignantmesotheliomaofpleural originwas
erformed by consulting the Medline and National Cancer Institute
lectronic databases. Search terms used included “mesothelioma”
medical subject heading (MeSH)) with the subheading “drug
herapy,” combined with “drug therapy” (MeSH), “chemotherapy”
MeSH), and “antineoplastic agents” (MeSH), and the text words
mesothelioma” and “second line”. Those terms were combined
ith the search terms for the following study designs and publica-
ion types: randomized controlled trials; controlled clinical trials;
hase II or III clinical trials; andmulticenter or comparative studies.
In addition, conference proceedings of the annual American
ociety of Clinical Oncology (ASCO), the annual European Society
edical Oncology (ESMO) and the bi-annual World Lung Can-
er Conference (WCLC) meetings for the years 2010–2014 were
earched for abstracts of relevant trials.
The criteria of eligibility of the articles were the following: to
ocus only on patients with MPM; to be related to the study of
ingle or combined cytotoxic and/or targeted or biological agents,
dministered by systemic routes; to be published in the English
anguage between January 2000 and July 2014; to be a prospective
ingle or randomized phase II or phase III trial, with a minimum
f 14 patients included. If less than 14 patients were included in
prospective phase II trial, the study could be considered as eligi-
le if at least one objective response was observed when targeting
response rate of 20%, according to the Gehan’s design for phase
I studies [11]. We assumed that a chemotherapeutic agent had a
linical potentially useful activity in a trial if its objective response
ate was at least 20% and we considered that a study was negative
f the upper limit of the 95% conﬁdence interval (CI) of the response
ate was ≤20%. It was considered as positive if the lower limit of
he 95% CI was >20% and as not conclusive but potentially positive
f the upper limit of the 95% CI was >20% but the lower limit <20%.
or targeted andbiological agents,we assumed that they had a clin-
cal potentially useful activity if the reported disease control rate
DCR= rate of OR+ stable disease) was at least 50% and we consid-
red that a study was negative if the upper limit of the 95% CI of the
esponse rate was ≤50%. It was considered as positive if the lower
imit of the 95% CI was >50% and as not conclusive but potentially
ositive if the upper limit of the 95%CIwas >20%but the lower limit
20%.
Phase II trials with chemotherapy were grouped according to
he following categories: single-agent chemotherapy, combination
hemotherapy. Phase II trials with targeted and biological agents
ere grouped according to the predominant hallmark pathway
nvolved: growth, angiogenesis, immunomodulation, invasion and
etastasis, apoptosis [12].
The response rates of the non-comparative trials were summed
nd averaged by category.
. Results
.1. Second-line chemotherapy in MPM
We retrieved 86 articles matching the search criteria. Of these,
0 reported on phase II and phase III prospective clinical trials,
f which one included less than 14 patients. Another 6 articles
ere found by cross referencing, of which 2 in overlaying patient
roups, 2 included less than 14 patients, 1 included 15 patients, but
ith results of ﬁrst- and second-line therapy. A total of 10 articlesncer 89 (2015) 223–231
reporting on 1251 patients treatedwith second-line chemotherapy
in MPM were eligible for this review (Table 1).
In an unplanned subgroup analysis of patients treated in the
pivotal registration phase III trial, Manegold et al. reported a signif-
icantly prolonged survival in the patients treated with post-study
chemotherapy [13]. Eighty-four patients (37.2%) of the cisplatin
and pemetrexed arm and 105 patients (47.3%) from the cisplatin
arm received post-study chemotherapy. The median time to start
post-study chemotherapy after completion of ﬁrst-line therapy
was 3.6 months in the cisplatin/pemetrexed group and 0.7 months
for the cisplatin group. According to that analysis, 62% of the study
patients were treated with single agent post-study chemotherapy
(48 from the pemetrexed/cisplatin group and 70 from the cis-
platin group) and 38% received combination chemotherapy (36
from the cisplatin/pemetrexed group and 35 from the cisplatin
arm). Gemcitabine was mostly given as a single-agent. For patients
with post-study chemotherapy, MST was 15.3 months in the cis-
platin/pemetrexed group and 12.2 months for the cisplatin group.
These ﬁgures set the stage as they suggest a potential beneﬁt for
second line treatment. Only patients with complete data were
included in this analysis, leading to comparepopulationswith small
numbers reducing the statistical power of the analysis. Itmust nev-
ertheless be emphasized that thesedata have important limitations
due to a selection bias. Patients receiving second-line chemother-
apy are indeed a selected group in good clinical condition that often
beneﬁted of previous treatments.
Pemetrexed is of interest due to its role as ﬁrst-line therapy.
The international Expanded Access Program (EAP) was opened
before its commercial availability in 13 European countries and the
US to provide both chemo-naïve and pre-treated patients access
to pemetrexed, either as single agent therapy or in combination
with platinum and this at the discretion of the investigator [14,15].
The results of EAP were reported in several publications, whereby
results by treatment or treatment group were not always sepa-
ratelymentioned. In 396 pre-treated European patients, the overall
response rate (ORR) with single agent pemetrexed was 12.1%, and
the median time to progression (TTP) 4.9 months [14]. The 1-year
survival rate was 47.2%. Tolerability was good, suggested by the
average amount of cycles of more than 6. Hematological toxicity
was mild. No separate data on patients treated with the combina-
tion are reported. One hundred and eighty seven previously treated
US patients were included: 91 received pemetrexed monotherapy,
96 received cisplatin/pemetrexed combination therapy [15]. Previ-
ous regimens consisted of gemcitabine, cisplatin, carboplatin and
paclitaxel. The patients receiving combination chemotherapy were
on average younger and ﬁtter at baseline and had a higher response
rate to ﬁrst-line therapy. This is also reﬂected by ahigher number of
treatment cycles administered to the combination group. Response
data were available for 153 patients. ORR for the whole group was
19.6% with a RR of 32.5% for pemetrexed/cisplatin and 5.5% for
pemetrexed alone. SD was achieved in 36.3% and 41.1% of patients,
respectively. The median OS was 7.6 months with the combination
therapy, 4.1monthswith pemetrexedmono-therapy. Although the
RR of 5.5% in the pemetrexed alone group is low, it is compara-
ble to other single-agent regimens, as reported in a systematic
review [16]. In this series a selection bias is present, as patients
with co-morbidities and lower performance status were included,
who might otherwise have been assigned to the treatment with
combination platinum/pemetrexed. Another bias constitutes the
fact that inclusion criteria for an EAP are less stringent than for a
formal clinical trial.
Sørensen et al. evaluated the efﬁcacy of pemetrexed in
second-line after platinum-based chemotherapy in 39 patients
previously treated with platinum-based regimens without peme-
trexed [17]. Twenty-eight Danish patients were treated with
pemetrexedaloneand11Norwegianpatientswithpemetrexedand
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Table 1
Studies in second line treatment of mesothelioma with chemotherapy single agents or combinations.
Trial characteristics
Number Chronological
order
1 2 3 4 5 6 7 8 9
REF n◦ cf. reference list 23 22 19 21 18 17 14 15 20
Reference Authors Fazizi et al., JCO, 2003 Porta et al., Lung Cancer,
2005
Stebbing et al.,
Lung Cancer, 2009
Tourkantonis et al.,
Am. J. Clin. Oncol.,
2011
Jassem et al., J. Clin.
Oncol., 2008
Sørensen et al., J. Thorac.
Oncol., 2007
Taylor et al., J. Thorac.
Oncol., 2008
Jänne et al., J. Thorac.
Oncol., 2006
Giaccone et al., Eur. J.
Cancer, 2008
Phase II or III II, open-label,
non-comparative,
two-center
II, 3-stage,
single-institution
II, open-label,
non-comparative
II, open-label,
single-arm,
single-center
III, open-label,
randomized,
multicentre
II, open-label,
non-randomized,
multicentre
II, open-label,
non-randomized,
multicentre
III, open-label,
non-randomized,
multicentre
II, open-label,
non-comparative,
multicentre
Category Single-agent
chemotherapy,
combination
chemotherapy,
growth,
angiogenesis,
immunomodula-
tion, invasion and
metastasis,
apoptosis
Combination
chemotherapy
Combination
chemotherapy
Single agent Single-agent Single-agent or
combination
chemotherapy
Single-agent Single-agent or
combination
chemotherapy
Single-agent
chemotherapy
Agent Generic name
Regimen Dosage and
frequency of
administration
Raltitrexed
3mg/m2 +oxaliplatin
130mg/m2 q3w
Raltitrexed
3mg/m2 +oxaliplatin
130mg/m2 q3w
Vinorelbine
30mg/m2 q1w
Gemcitabine
1000mg/m2 +
docetaxel
80mg/m2 q2w
Pemetrexed 500mg/m2
q3w+BSC versus BSC
Pemetrexed 500mg/m2
q3w or pemetrexed
500mg/m2 + carboplatin
AUC 5 q3w
Pemetrexed
500mg/m2 q3w
Pemetrexed 500mg/m2
q3w or pemetrexed
500mg/m2 + cisplatin
75mg/m2 q3w
ZD0473 120mg/m2 or
ZD0473 150mg/m2
Sample size N 70 14 63 37 243 39 493 187 47
Patient characteristics
Male (n) N 51 11 59 30 96 35 374 149 41
Male (%) % 74 78.5 93.6 81.1 78 90 75.9 80 85
Age (median) Number 60 59.5 59 66 60 62 63 66 59
Age (range) Numbers 43–74 42–71 29–77 44–81 32–78 30–77 31–85 27–87 37–75
WHO PS 0–1 Number 57 9 49 37 60 35 250 n.a. 36
WHO PS 0–1 % 81 64.2 77.8 100 48.8 90 64.5 n.a. 77
Tumor characteristics
Epithelioid N 46 8 47.8 27 90 33 351 n.a. NR
Epithelioid (%) % 66 57.1 62 73 73.2 85 71.2 n.a. NR
First line treatment AFP, antifolate
platinum; D,
doxorubicin-based;
O, other
Cisplatin Doxorubicin +
rampirnase;
doxorubicin;
cisplatin + gemcitabine;
cisplatin +pemetrexed;
imatinib mesylate; mit-
omycin +methotrexate
+mitoxantrone; s.c.
interleukin-
2+ interferon-
Carboplatin
+pemetrexed
Vinorelbine + cisplatin;
vinorel-
bine + carboplatin;
gemc-
itabine + carboplatin;
gemc-
itabine + caelyx + carboplatin
Gemcitabine; cisplatin;
carboplatin; paclitaxel;
navelbine; docetaxel;
doxorubicin
Best response to 1st line
R/
% PD PR PD PR
Treatment characteristics
Response criteria RECIST 1.0; RECIST
1.1; modiﬁed
RECIST
NA RECIST 1.0 RECIST 1.0 NS Modiﬁed RECIST RECIST, SWOG, WHO RECIST RECIST
Number of responses to
2nd line
N 3 0 10 7 48 30
ORR (%) to 2nd line % 20 16 18.7 12.1 19.6 0
Number of SD to 2nd
line
N 4 43 23 50 182 59 0
SD rate (%) to 2nd line % 28.6 68 40.7 46 38.6 66
DCR to 2nd line % 84 59.3 58.1 58.2
Median PFS Months 6.2 2 7 3.6 6.1 4.9 2.5
PFS @ 1 year %
Median OS Months 10.1 3.5 9.6 16.2 8.4 9.5 6.8
OS @ 1 year % 40 36 47.2
Toxicity
Grade 3–4 hematotoxa N 21% hematox; 7% GI tox;
7% neurotox;
72% hematox; 11%
GI tox; 8% neurotox
46% hematox; 11%
GI tox; 8%
neurotox; 5%
respiratory tox
11% hematox; 9% GI tox;
18% respiratory tox
18% hematox 43% respiratory tox
a Indicates that no grade 5 toxicity was reported.
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arboplatin. Treatment with pemetrexed monotherapy gave a RR
f 21% with a median TTP 4.9 months (range 4–92) and OS 9.8
onths (4–99 weeks), 1-year survival rate was 36%. In the peme-
rexed/carboplatin group the RR was 18%, the median TTP 7.4
onths and OS 9.1 months. The authors conclude that second line
reatment with single agent pemetrexed as in pemetrexed naive
atients, is justiﬁed.
A large multicentre phase III study in advanced mesothelioma
as designed to compare the efﬁcacy and safety of pemetrexed
nd best supportive care (BSC) [18]. Patients with relapsed MPM
fter ﬁrst-line chemotherapy (excluding pemetrexed) were ran-
omized between pemetrexed 500mg/m2 every 21 days or BSC
lone. Treatment was given for eight cycles or until progres-
ive disease (PD). The primary endpoint of the study was OS.
econdary endpoints included RR, TTP, progression free survival
PFS), time to treatment failure and toxicity. Of the 243 patients
ncluded, the 143 patients receiving pemetrexed showed a PR in
8.7%. RR was 19.2% with pemetrexed versus 1.7% in the BSC
rm, respectively. The median TTP was 3.8 months versus 1.5
onths. The median OS was not signiﬁcantly different with 8.6
onths versus 9.8 months, maybe due to the signiﬁcant imbal-
nce in post-study chemotherapy between the arms. This phase
II trial demonstrated that pemetrexed in second-line delays dis-
ase progression for advanced MPM, reﬂected by the DCR of
lmost 60% in the pemetrexed arm and 19.2% in BSC arm. The
hemotherapy was well tolerated and toxicities were mild. The
SC arm had a disproportionate number of patients who dis-
ontinued the study before response evaluation compared to the
emetrexed plus BSC arm. After study-discontinuation chemother-
pywas allowed. Signiﬁcantlymore patients in the BSC arm (51.7%)
eceived post-discontinuation chemotherapy than in the experi-
ental arm (28.5%). Platinum, pemetrexed and gemcitabine were
he most commonly used agents.
In a phase II, open-label single-agent trial, the safety and efﬁ-
acy of weekly vinorelbine was assessed [19]. Patients with a good
erformance status and prognostic score according to EORTC were
ncluded. Sixteen percent of 63 pre-treated patients had a par-
ial response to vinorelbine. Forty-three patients (68%) had a SD
eﬁned as no evidence for progression for 6months. TheOSwas 9.6
onths. Over half of the patients experienced a grade 3/4 toxicity.
edian interval between the end of ﬁrst-line chemotherapy and
he start of weekly vinorelbine was 6 months. No separate analysis
as performed in the patients pre-treated with pemetrexed.
Picoplatin was designed to overcome resistance mechanisms.
phase II, open-label, non-comparative, multicentre study was
esigned to evaluate the activity and tolerability of picoplatin in
7 MPM pre-treated patients [20]. The majority had advanced
isease and 83% received prior platinum-based therapy. Of 43
valuable patients no CR or PR was observed. This resulted in a
R of 12% of patients with a minor response, deﬁned by reduc-
ion of lesion size ≥10% but <50%. SD was seen in 44%. The median
TP was 2.5 months, OS was 6.7 months. Picoplatin demonstrated
manageable tolerability proﬁle. However, no complete or partial
esponseswere seen. The activity of picoplatin is comparable to cis-
latin in ﬁrst-line therapy and warrants no further investigation in
PM.
The combination gemcitabine and docetaxel was evaluated in
7 pre-treated patients [21]. Docetaxel 80mg/m2 and gemcitabine
000mg/m2 were given on day 1 and 14 of a 28-day cycle. Support
f granulocyte colony-stimulating factor was allowed. The primary
ndpointwas RR and the secondary endpoints included TTP andOS.
n 7 patients (18.9%) a PRwas seen, SD in 23 patients (62.2%) and PD
n 7 patients (18.9%). The median TTP was 7 months (range 5.8–8.2
onths) with a median survival of 16.2 months (range 13–19.3
onths). Haematologic toxicity occurred mostly with grade
–4 neutropenia. However, the combination of gemcitabine andncer 89 (2015) 223–231
docetaxel is tolerable and safe and can be an option in pre-treated
patients.
The combination of raltitrexed and oxaliplatin was investi-
gated in 2 studies. Porta reported results of 14 patients who were
treated with raltitrexed/oxaliplatin [22]. In this group, prior treat-
ment mainly consisted of cisplatin and doxorubicin. No objective
responses were seen and disease stabilization was observed in 4
patients. The 10 other patients were progressing, with a median
time to progression of 1.9 months. The median OS was 6.7 months.
Although the combination of raltitrexed/oxaliplatin has RRs in
treatment naive patients of 30–35%, it failed to showany signiﬁcant
activity in second-line treatment of MPM.
Fizazi et al. performed an open-label, non-comparative, multi-
centre, phase II trial of 15 pre-treated patients and 55 chemo-naïve
MPM [23]. All pre-treated patients had prior cisplatin and a
minimum of 2 chemotherapy regimens and were treated with
raltitrexed/oxaliplatin. The RR was 20%, the median TTP 6.2
months, and the median OS 10.1 months. The combination showed
responses even in the cisplatin-resistant patients. The one-year OS
was 40%. The toxicity was manageable; the most reported toxicity
was asthenia. Grade 3 anemia and neutropenia were observed only
in 4.1% and 6.9% of the patients, respectively.
In vitro data suggest that valproic acid, a histone deacetylase
inhibitor (HDACi), has a pro-apoptotic effect and synergised with
doxorubicin to induce apoptosis in malignant mesothelioma cells
[24]. In a phase II trial, 45 patients pre-treated with at least one
chemotherapy regimen including platinum derivatives, regardless
response, received the combination of valproic acid and doxoru-
bicin [25]. The RR was 16%. The median PFS and the median OS
was 2.5 months and 6.7 months, respectively. Two deaths were
related to toxicity, both in patients with poor PS. The authors com-
mented that this combination seems to be an effective second-line
treatment in patients with good PS.
3.2. Second line targeted and biological agents
As an alternative to a cytotoxic treatment, researchers have
tested inhibitors of other hallmarks pathways in MPM, from
oral tyrosine kinase inhibitors over epigenetic compounds to
immunotherapy (see Table 2).
3.3. Genetics
Recently, somatic and germ line genetic alterations have been
identiﬁed that may lead to MPM itself or increase the susceptibility
to asbestos carcinogenesis. MPM is particularly characterized by
the loss of tumor suppressor genes, rather than gain of function
mutations. The most frequently mutated tumor suppressor genes
are discussed here and their possible implications for therapeutic
interventions [26].
Mutations in the neuroﬁbromatosis type 2 gene (NF2) are found
in 35–40% of MPM. The NF2 gene encodes a tumor suppressor gene
merlin, a member of the band 4.1 family of cytoskeletal linker pro-
teins. When the NF2 gene is mutated, non-functional versions of
merlin will be produced, being unable to function properly. Mer-
lin mediates the contact dependent inhibition of cell proliferation
in normal cells and interacts with more than 30 other intracellular
proteins. Together with Focal Adhesion Kinase (FAK) it also inhibits
the growth of cancer stem cells. Other key pathways are the mam-
malian target of rapamycin (mTOR); the Hippo pathway, which is
important in cell proliferation, and extracellular signal-regulated
kinase (ERK) pathways [26,27].mTOR activity is up regulated in the absence of merlin, leading
to increased cell proliferation. In the SWOG 0722 phase 2 trial the
mTOR inhibitor everolimus was tested in 2nd or 3rd line. It did not
meet itsprimaryendpoint, an improvementof4months inPFS from
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Table 2
Studies in second line treatment of mesothelioma with targeted agents or immunomodulating drugs.
TKI
Trial characteristics
Number Chronological
order
1 2 3 4 5 6 7 8
REF n◦ cf. reference list 28 33 39 40 41 42 43 44
Reference Authors SWOG 0722,
Garland ea, ASCO
annual meting
VANTAGE-014,
Krug et al., Lancet
Oncology
Kindler et al.,
Journal of Clinical
Oncology
CALGB 30307,
Dubey et al., JTO
NCIC, Laurie et al.,
JTO
CALGB 30107,
Jahan et al., Lung
Cancer
University of
Chicago phase II
consortium,
Campbell et al.,
Lung Cancer
SWOG S0509,
Garland, JTO
Phase II or III II III II (randomized) II II II II II
Agent Generic name Everolimus Vorinostat Bevacizumab Sorafenib Sunitinib Vatalanib Cediranib Cediranib
Regimen Dosage and
frequency of
administration
Daily oral 1× 10mg Oral 2× 300mg, 3
days/week vs
placebo
Gemcitabin/cislatin
q3w±bevacizumab
15mg/kg
Daily oral 2×
400mg
Daily oral 1× 50mg
4w, 2w rest
Daily oral 1×
1250mg
Daily oral 1× 45
and 1× 30mg
Daily oral 1× 45mg
Sample size N 57 661 108 50 17 47 50 47
Patient characteristics
Male (n) N 43 283/270 39/46 35 14 43 42 38
Male (%) % 75 86/81 74/84 70 82 90 84 81
Tumor characteristics
Epithelioid N n.a. 274/269 39/37 37 10 36 36 28
Epithelioid (%) % 61 83/81 74/67 74 59 77 72 60
Best response to 1st line R/ % n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Treatment characteristics
Response criteria Modiﬁed RECIST + + + + + + + +
Remark Did not reach
primary endpoint
Higher
pretreatment
plasma VEGF
associated with
shorter PFS
Dose was lowered
after 15 patients to
30mg due to
toxicity
2 patients had 91%
and 56% tumor
shrinkage
ORR (%) to 2nd line % – 1/<1 25/22 6 0 6 10 9
SD rate (%) to 2nd line % – n.a. 51/60 54 72 34 34
PFS @ 1 year % n.a. Median 6.9/6.0 mo Median PFS 3.6 mo Median PFS 2.8 mo Median PFS 4.1 mo Median PFS 1.8 mo Median PFS 2.6 mo
Median OS Months 5mo 8mo vs 7mo 15.6mo vs 14.7mo 9.7mo 8.3mo 10.0mo 4.4mo 9.5mo
Toxicity
Grade 3–4 N n.a. 16 vs 8% fatigue; 11
vs 14% dyspnea
26.4/14.6 24% fatique, 12%
rash, 8% dyspnea
29% fatique, 12% GI,
5% hand-foot
15% nausea, 11%
elevated ALAT
87% in 45mg
group, 43% in
30mg group
64% fatique, 64%
diarrhea, 70%
hypertension
Grade 5 toxicity N 1 1/0 n.a. 0 0 0 0 0
% 2 0 0 0 0 0
TKI
Trial characteristics
Number 9 10 11 12 13 14 15 16 17
REF n◦ 45 46 52 53 49 50 48 47 61
Reference Nowak et al., JTO NVALT 5,
Buikhuisen et al.,
Lancet Oncology
SWOG, Garland
et al., JCO
Jackman et al.,
Cancer
Mathy et al., Lung
Cancer
CALGB 30601,
Dudek, JTO
Nowak et al., Lung
Cancer
Gregorc et al., JCO ICORG 05–10, Fennell
et al., JTO
Phase II III randomized II II II II II II II
Agent Sunitinib Thalidomide Erlotinib Erlotinib
bevacizumab
Imatinib Dasatinib BNC 105P NGR-hTNF Bortezomib
Regimen Daily oral 50mg
4w, 2w rest
Daily oral
200mg/active
supportive care
Daily oral 1×
150mg
Daily oral erlotinib
1× 150mg,
bevacizumab
15mg/kg iv d1 q21
Daily oral
400–800mg
Daily oral 2×
70mg, after 23 pts
2× 50mg due to
toxicity
16mg/m2 iv d1, 8
q21d
0.8g/m2 iv q
21d/and q7d
1.6mg/m2 iv d1, 8, 15,
22 q35d
Sample size 51 222 61 24 25 43 30 43/14 21
Patient characteristics
Male (n) 44 92/95 47 15 80 31 27 27/’8 20
Male (%) 83% 83/86 75 62 20 72 90 63/57 87
Tumor characteristics
Epithelioid 39 95/94 28 16 20 33 20 34/11 16
Epithelioid (%) 73 86/85 44 67 80 77 67 79/79 70
Best response to 1st line R/ n.a. No PD n.a. n.a. n.a. n.a. n.a. PR 12/14 SD 56/57 n.a.
Treatment characteristics
Response criteria − + + + − + + + +
Remark Study was unable
to ﬁnd biomarkers
of response
33 patients had
measurable disease
Weekly NGR-hTNF
warrant additional
evaluation
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Table 2 (Continued )
ORR (%) to 2nd line 12 0 0 0 0 5 3 2/0 5
SD rate (%) to 2nd line 65 n.a. 42 50 6 28 43 42/50 5
PFS @ 1 year Median TTP 3.5 mo Median TTP
3.6/3.5mo
6% 6% Median TTP 63
days
2.3% at 48 weeks Median PFS 1.5mo Median PFS
2.8/3.0mo
Median PFS 2.1mo
Median OS 6.1mo 10.6/12.9mo 10mo 5.8mo 13mo 6mo 8.2mo 12.1mo 5.8mo
Toxicity
Grade 3–4 9%
thrombocytopenia,
7% neutropenia
2/0% constipation,
4/1% fatique, 2/0%
neurosensory
18% rash, 8%
diarrhea, 5% fatigue
17% rash, 8%
diarrhea
20% peripheral
edema
0 33% grade 3 or 4 No grade 3–4
drug-related
toxicities
Grade 3 – 26%
Grade 4 – 17%
Grade 5 toxicity 1 0 1 0 0 0 2 0 2
2 0 1 0 0 0 6 0 9
Immunotherapy
Trial characteristics
Number Chronological order 1 3 4
REF n◦ cf. reference list 54 56 60
Full reference Authors/title/Journal (Vancouver style) Calabro et al., Lancet Oncology Alley et al., AACR annual meeting Hassan et al., Science Translational Medicine
Phase I/II or III II IB I/II
Agent Generic name Tremelimumab Pembrolizumab SS1P, pentostatin, cyclophosphamide
Regimen Dosage and frequency of administration 10mg/kg iv q 4 weeks 10mg/kg q2w Different dosing schedules
Sample size N 29 25 10
Patient characteristics
Male (n) N 21 17 4
Male (%) % 72 68 44
Tumor characteristics
Epithelioid N 25 15 9
Epithelioid (%) % 86 60 100
Remarks % Durable partial response lasting 6 and 18mos 80%≥1 line 2 peritoneal mesothelioma, all patients tumor had
expression of mesothelin
Treatment characteristics
Response criteria RECIST 1.0; RECIST 1.1; modiﬁed RECIST + + −
Remark PET evaluation
ORR (%) % 7 20 30
Disease Control Rate % 31 72 n.a.
PFS @ 1 year % Median PFS 6.2mo n.a. 20
Median OS Months 10.7m n.a. 8.8
Toxicity
Grade 3–4a % 7% GI tox; 3% peripheral neurotox 4% liver tox; 4% hematotox 9% non-cardiac chest pain, 9% pleuritic pain, 9% back
pain. 100% lymphopenia, 18% transaminitis
a Indicates that no grade 5 toxicity was reported.
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0% to 50% (4months PFS 34%) [28]. In viewof the compensatory up
egulation of PI3K seenwithmTOR inhibition alone, dual inhibition
f both mTOR and PI3K, maybe a better approach. This was tested
n a phase 1 study in patients with mesothelioma. An expansion
ohort was created with the dual PI3K and mTOR inhibitor GDC-
980 with encouraging results [29].
Further exploration of the mTOR signaling pathway involves
ocal adhesion kinase (FAK). This enzyme is involved in cell migra-
ion, adhesion and invasion. Merlin, the protein encoded by NF2,
locks FAK activation, so there is higher activation of FAK in tumors
ith merlin loss. VS-6063 is an inhibitor of FAK and appears to
lock the growth of mesothelioma cells in both xenografts and cell
ines. This drug appears to work best in merlin deﬁcient cell lines,
ut there still are signs of inhibition in wild type mesothelioma
ell lines [30]. These preclinical data led to the randomized phase
maintenance study of VS6063 that is ongoing (NCT01870609),
he estimated study completion date is December 2016. Primary
ndpoint will be PFS and OS.
BRCA1-associated protein-1 (BAP1) is inactivated in at least a
uarter of MPM, although a number of different mutations have
een identiﬁed [31]. BAP1 has a role in DNA repair, control of gene
xpression through histone modiﬁcation and enhancing progres-
ion through the G1-S checkpoint [32]. The role of BAP1 in histone
odiﬁcation is of interest since it raises the possibility that his-
onedeacetylase inhibitors (HDAC)mayhaveactivity in thedisease.
owever the lack of clinical response in a large randomized phase
trial of the HDAC inhibitor vorinostat deny HDAC inhibitors to be
n important strategy in tumors with BAP1 loss [33].
.4. Vascular targeted drugs
Tumor growth is strongly dependent upon angiogenesis and
ewly formed feeding vessels are required when the tumor size
xceeds a diameter of 2mm [34]. Mesothelioma cells often express
ascular endothelial growth factor receptors (VEGFR) and produce
rowth factors like VEGF and basic ﬁbroblast growth factor (bFGF)
35]. Patients with MPM express serum VEGF levels that are higher
ompared to other solid tumors or healthy individuals [36]. High
erum levels of VEGF and bFGF and microvessel density have been
dentiﬁed as negative prognostic factors for MPM [37,38].
For these reasons many studies using anti-angiogenic treat-
ents inmalignantmesotheliomahave beenpublished, butmostly
ith disappointing results. In a randomized phase II study inves-
igating the effect of bevacizumab, a VEGF monoclonal antibody,
n patients receiving cisplatin and gemcitabine, bevacizumab did
ot improve outcome [39]. Although in this study an exploratory
ubset analysis showed improved survival for the bevacizumab
hemotherapy regimen in patients with low circulating levels of
EGF. Other phase II studies tested drugs with anti angiogenic
roperties like sorafenib [40], sunitinib [41], vatalanib [42] and
ediranib [43], all ofwhich reported lowresponse rates and failed to
how any anti tumor activity. One phase II study showed modest
ctivity of cediranib after previous platinum-based therapy. Four
atients (9%) in this single arm study showed a partial response,
hich did not meet the pre-speciﬁed 20% response rate of interest.
owever, there was marked shrinkage of bulky tumors in two of
he four patient responders [44]. This was the reason to proceed
ith a larger randomized phase II trials testing cediranib in com-
ination with pemetrexed and cisplatin. A second phase II study of
unitinib as second-line therapy reported modest activity in pro-
ressing patients, butwas unable to identify any serumbiomarkers
f response in angiogenesis pathways [45]. A large randomized
hase III study examined the oral antiangiogenic drug thalidomide
n a switch maintenance setting. Patients with malignant mesothe-
ioma who did not show progression after ﬁrst line chemotherapy
ere randomized to receive thalidomide or active supportive carencer 89 (2015) 223–231 229
until progression. The addition of thalidomide did not show any
beneﬁt in time to progression or overall survival [46].
3.5. Immunomodulation and other pathways
The vascular disrupting agent NGR-hTNF is a combination of
tumornecrosis factor (TNF), regulator of immunecells and inhibitor
of tumourigenesis and asparagines–glycine–arginine (NGR). It
selectively targets TNF to an aminopeptidaseN/CD13 isoformover-
expressed by endothelial cells in solid tumors. A single agent phase
2 trial in 57 pretreated MPM patients showed a disease control
rate of 46%, these patients experienced a median progression-
free time of 4.4 months [47]. These results lead to a randomized
phase 2 study NGR015 in which pemetrexed pretreated patients
receive second line chemotherapy vinorelbin or doxorubicin com-
bined with either NGR-hTNF or placebo. The trial has completed its
accrual and results are awaited (NCT01098266). Another incom-
plete study with NGR-hTNF is the randomized phase 2 trial NGR
019, with either weekly maintenance NGR-hTNF or placebo in
patients not progressing after 6 cycles of pemetrexed containing
therapy (NCT01358084).
BNC105P is a tubulin polymerization inhibitor that selectively
disrupts tumor vasculature and suppresses cancer cell prolifer-
ation. In a second line phase 2 study BNC105P was given until
progression. Results were disappointing with a median PFS of 1.5
months. These results did not warrant further research as a single
agent [48].
Plateletderivedgrowth factor (PDGF) is agrowth factor inducing
mesothelial cell proliferation through the cell membrane recep-
tor platelet derived growth factor receptor (PDGFR). A high serum
PDGF in patients with MPM is an independent factor of poor prog-
nosis. Imatinib and dasatinib are TKI inhibiting the PDGFR, but did
not showclinical activity as single agents in phase II studies [49,50].
EGFR plays a role in cell proliferation, differentiation, migra-
tion, adhesion and survival. EGFR is overexpressed at protein level
in more than 50–95% of the patients. Activating driver mutations
of the tyrosine kinase residue, which translates the signal down-
stream and makes the tumor addicted to growth are rare in MPM
[51]. The EGFR TKI erlotinib and the combination of erlotinib and
the chimeric mouse–human antibody targeting the extracellular
domain of EGFR, cetuximab were studied in 2 phase 2 studies.
Results were disappointing with no patients achieving a partial
response [52,53].
The anti-cytotoxic T lymphocyte antigen 4 (CTLA4) spe-
ciﬁc monoclonal antibody tremelimumab is a new class of
immunomodulatorymonoclonal antibody. It targets the regulatory
molecules expressed on immune cells to enhance the anti-tumor
activity of T-cells. In a single arm phase 2 study, twenty-nine
patients were enrolled with unresectable MPM with progressive
disease after ﬁrst-line platinum-based regimen [54]. Although the
study did not meet its primary endpoint, it did show encouraging
clinical activity. Disease control was observed in 9 patients (31%)
with a median progression free survival of 6.2 months and median
overall survival of 10.7 months. Two patients (7%) had durable
partial responses, respectively 6 and 18 months. Another phase 2
study in which also 29 patients were treated with tremelimumab
10mg/kg every 4 weeks showed similar results [55]. A random-
ized, double blind, placebo controlled, phase 2 study is currently
evaluating tremelimumab with the primary objective of demon-
strating a 50% improvement in overall survival from 7 to 10.5
months (NCT01843374). After a recent interim analysis the accrual
target was increased to 542 patients.A checkpoint inhibitor, pembrolizumab, was tested as single
agent in a phase I/II study and reported in abstract [56]. In 25
patients out of 38 patients with positive staining for PD-L1, pem-
brolizumab treatment (10mg/kg q2wk) resulted in a ORR of 20%
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nd 72% had control of the disease. Ten patients could be treated
or over 9 months with low toxicity. Only 1 grade 3 toxicity for ALT
nd1 for thrombocytopeniawere observed. These results have lead
o a randomized phase II study (NCT02399371) currently open for
ecruitment in second line.
Mesothelin is an antigen, which is highly expressed on certain
umor cells like mesothelioma, ovarian and pancreatic carcinoma.
n normal tissues its expression is limited tomesothelial cells lining
he pleura, the peritoneum and pericardium [57,58]. Mesothe-
in has been used to target MPM in different ways. SS1P is a
ecombinant immunotoxin consisting of an anti-mesothelin vari-
ble fragment linked to PE38, a portion of Pseudomonas exotoxinA.
n the preclinical setting it has shown to be cytotoxic to mesothelin
xpressing cell lines [59]. In the ﬁrst clinical trials, the vast major-
ty of treated patients developed antibodies against SS1P after only
ne cycle of treatment, precluding its continued use as a therapeu-
ic agent. To overcome this problem, patients were pretreated with
entostatin and cyclophosfamide; chemotherapeutic agents that
peciﬁcally deplete lymphocytes, thereby preventing the forma-
ion of antitoxin antibodies. This resulted in remarkable improved
linical outcomes. Of 10 patients with chemotherapy–refractory
esothelioma, 3 had a major tumor regression, with 2 ongoing at
5 months, and to respond to chemotherapy after discontinuing
mmunotoxin therapy in an unexpected way [60]. The develop-
ent of anti-pseudomonas antibodies have urged the researchers
o develop a second-generation immunotoxin where the B-cell
ctivating sitesof themoleculehavebeen replacedby less immuno-
enic residues.
Bortezomib, a proteasome inhibitor, was tested as single agent
n a multicenter study. Of the 23 patients included, only 1 patient
esponded (4.8%). The PFS was 2.1 month with an OS of 5.8 months
61]. Single agent therapy showed insufﬁcient activity to continue
esearch in unselected patients.
. Conclusions
The development of effective treatments in MPM has been
otoriously slowandunsuccessful. Itwas until 2003when two ran-
omized phase III studies showed that the combination of a platin
ompound and anti-folate improved PFS, OS and did not impair
he quality of life. Unfortunately the disease recurred in over 80%
f the patients at the 2-year follow up mark. This leads to new
tudies inMPM in the second line setting. The classical, chemother-
py compounds tested, did not really show any improvement and
ore emphasis was given to drugs that might stabilize the disease
ith manageable toxicity. Only one phase III study was reported
here pemetrexed was compared to BSC. The ﬁnal analysis did
ot show any beneﬁt in OS but an improvement in disease control
as observed. Crossover from the BSC arm to pemetrexed proba-
ly accounts for this observation. Other single agent drugs did not
mpress the scientiﬁc community with activity or tolerability.
Only a limitednumber of randomizedphase II studieswith com-
ination therapy have been examined. They focused mostly on
combination with pemetrexed and platin compound. Although
cceptable in patients with a good PS, none of these have been
dopted as standard therapy in second line.
The following conclusions regarding second line chemotherapy
n MPM can be drawn:
Single agent vinorelbine or pemetrexed are acceptable 2nd line
agents for patients relapsing after a ﬁrst line platinum combina-
tion depending on its association with pemetrexed or not.
The low reported activity of the drugs in second line warrants
referral ofﬁtpatients toparticipate in clinical trials [11]. The latter
should preferably consist of randomized phase 2 trials, whereby
[ncer 89 (2015) 223–231
patientswill be randomly allocated to either the new single agent
or one of the single agents with documented activity.
With the identiﬁcation of driver mutations in lung cancer, high
expectations were also set for mesothelioma. Unfortunately the
TKI’s didnotperformas expected.Whilehigh levels of EGFRexpres-
sion were observed in most MPM samples, no mutations in exon
19 of deletion in exon 21 were observed. Pathways of interest in
MPM have been narrowed down to mTOR and PI3CA, while others
have been tested without a clear success. New approaches like the
use of immune checkpoint inhibitors and immunotoxins seem to
be more effective. Studies in maintenance setting or in second or
third line are now in place and seem to be very active in a subset of
patients. The problem remains how to select patients suitable for
this kind of therapy.
It is clear that the new developments in immunotherapy and
pathway modulation will open new perspectives for treatment.
Since single agent treatment is not expected to lead to long-term
disease control, combination treatments must be tested. This must
bedonewith care andproper planning since thenumber of patients
with MPM who are suitable candidates for studies is relatively
small.
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